Zimmer Biomet Holdings, Inc. (ZBH)
Stock Price Chart
Key Info
| Market Cap | 31.27B |
| Revenue (ttm) | 7.06B |
| Net Income (ttm) | -151.90M |
| Shares Out | 207.28M |
| EPS (ttm) | -0.74 |
| PE Ratio | n/a |
| Forward PE | 18.94 |
| Dividend | $0.96 |
| Dividend Yield | 0.64% |
Stock Quote
| Trading Day | November 30 |
| Last Price | $150.87 |
| Previous Close | $150.02 |
| Change ($) | 0.85 |
| Change (%) | 0.56% |
| Day's Open | 150.24 |
| Day's Range | 148.87 - 150.96 |
| Day's Volume | 201,476 |
| 52-Week Range | 80.12 - 159.39 |
More Stats
| Market Cap | 31.27B |
| Enterprise Value | 38.59B |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | Sep 29, 2020 |
| Shares Outstanding | 207.28M |
| Float | n/a |
| EPS (basic) | -0.73 |
| EPS (diluted) | -0.74 |
| FCF / Share | 3.68 |
| Dividend | $0.96 |
| Dividend Yield | 0.64% |
| Earnings Yield | n/a |
| FCF Yield | 2.44% |
| Payout Ratio | n/a |
| Shares Short | 2.02M |
| Short Ratio | 1.57 |
| Short % of Float | n/a |
| Beta | 1.34 |
| PE Ratio | n/a |
| Forward PE | 18.94 |
| P/FCF Ratio | 41.04 |
| PS Ratio | 4.43 |
| PB Ratio | 2.61 |
| Revenue | 7.06B |
| Operating Income | 8.30M |
| Net Income | -151.90M |
| Free Cash Flow | 761.90M |
| Net Cash | -7.32B |
| Net Cash / Share | -35.33 |
| Gross Margin | 81.10% |
| Operating Margin | 0.12% |
| Profit Margin | -2.20% |
| FCF Margin | 10.78% |
| ROA | 2.36% |
| ROE | -1.25% |
| ROIC | 0.20% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,982 | 7,933 | 7,803 | 7,668 | 5,998 | 4,673 | 4,623 | 4,472 | 4,452 | 4,220 |
| Revenue Growth | 0.62% | 1.66% | 1.76% | 27.85% | 28.34% | 1.08% | 3.39% | 0.45% | 5.49% | - |
| Gross Profit | 5,730 | 5,661 | 5,670 | 5,287 | 4,197 | 3,431 | 3,357 | 3,347 | 3,330 | 3,208 |
| Operating Income | 1,138 | 33.80 | 799 | 821 | 467 | 1,037 | 1,069 | 1,047 | 1,024 | 917 |
| Net Income | 1,132 | -379 | 1,814 | 306 | 147 | 720 | 780 | 755 | 761 | 597 |
| Shares Outstanding | 205 | 204 | 202 | 200 | 187 | 169 | 170 | 175 | 188 | 200 |
| Earnings Per Share | 5.47 | -1.86 | 8.90 | 1.51 | 0.77 | 4.20 | 4.54 | 4.29 | 4.03 | 2.97 |
| EPS Growth | - | - | 489.4% | 96.1% | -81.67% | -7.49% | 5.83% | 6.45% | 35.69% | - |
| Dividend Per Share | 0.96 | 0.96 | 0.96 | 0.96 | 0.88 | 0.88 | 0.80 | 0.72 | - | - |
| Dividend Growth | 0% | 0% | 0% | 9.09% | 0% | 10% | 11.11% | - | - | - |
| Operating Cash Flow | 1,586 | 1,747 | 1,582 | 1,632 | 850 | 1,061 | 963 | 1,152 | 1,177 | 1,194 |
| Capital Expenditures | -721 | -439 | -493 | -530 | -364 | -342 | -293 | -264 | -269 | -280 |
| Free Cash Flow | 865 | 1,308 | 1,089 | 1,102 | 486 | 718 | 670 | 888 | 908 | 913 |
| Cash & Equivalents | 618 | 543 | 524 | 634 | 1,624 | 1,696 | 1,808 | 1,556 | 1,224 | 934 |
| Total Debt | 8,221 | 8,939 | 10,143 | 11,241 | 11,497 | 1,426 | 1,672 | 1,821 | 1,719 | 1,142 |
| Net Cash / Debt | -7,604 | -8,396 | -9,618 | -10,607 | -9,874 | 270 | 135 | -265 | -496 | -208 |
| Assets | 24,639 | 24,127 | 26,014 | 26,684 | 27,161 | 9,658 | 9,581 | 9,012 | 8,515 | 8,000 |
| Liabilities | 12,246 | 12,851 | 14,279 | 17,015 | 17,271 | 3,106 | 3,281 | 3,146 | 3,001 | 2,229 |
| Book Value | 12,388 | 11,271 | 11,736 | 9,669 | 9,888 | 6,550 | 6,297 | 5,861 | 5,507 | 5,771 |
Company Profile
Company Details
| Full Name | Zimmer Biomet Holdings, Inc. |
| Country | United States |
| Employees | 19,900 |
| CEO | Bryan C. Hanson |
Stock Information
| Ticker Symbol | ZBH |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NYSE: ZBH |
Description
Zimmer Biomet Holdings, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and office based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.